| abstract |
Disclosed is a pharmaceutical preparation which can reduce the tumorigenicity of a glioma stem cell that has resistance against anti-cancer agents and radioactive rays and can increase the sensitivity of the glioma stem cell to anti-cancer agents and radioactive rays. Specifically disclosed is a glioma stem cell differentiation promoter which comprises a substance capable of inhibiting a TGF-β-Sox4-Sox2 pathway, i.e., a pathway through which TGF-β can induce the expression of Sox4 and through which Sox4 can promote the expression of Sox2, in the glioma stem cell. |